Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System

Trends in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls

Nutrients, Journal Year: 2025, Volume and Issue: 17(1), P. 164 - 164

Published: Jan. 1, 2025

Background/Objectives: Despite the abundant body of evidence linking high-intensity interval training (HIIT) to cardiometabolic markers, little is known about how HIIT affects liver enzymes, particularly in obese adolescents. This study aimed investigate effects on metabolic dysfunction-associated steatotic disease (MASLD)-related biomarkers overweight/obese adolescent girls. Methods: Thirty-three girls (age, 17.0 ± 1.15 yr.; mass index, 33.3 4.77 kg/m2) were randomly assigned (n = 17) or control 16) groups. The group participated a nine-week program (three times weekly) without caloric restriction. Maximal aerobic speed, composition indexes, blood pressure, MASLD-related [liver enzymes (alanine aminotransferase (ALT) and aspartate (AST)), plasma lipids, uric acid, platelet count, homeostasis model assessment index for insulin-resistance (HOMA-IR)] examined at baseline after intervention. Results: Significant “time × group” interactions found systolic maximal ALT AST, glucose, HOMA-IR. resulted an increase speed (p 0.035) decrease lipids < 0.01), pressure 0.011), 0.013), AST 0.012), HOMA-IR but no significant changes acid count. None these markers changed group. Conclusions: improvement biomarkers. could be effective exercise therapy prevent reverse MASLD adolescents with obesity.

Language: Английский

---

Effects of Different Exercises Combined with Different Dietary Interventions on Body Composition: A Systematic Review and Network Meta-Analysis

Nutrients, Journal Year: 2024, Volume and Issue: 16(17), P. 3007 - 3007

Published: Sept. 5, 2024

Background: Exercise and dietary interventions are essential for maintaining weight reducing fat accumulation. With the growing popularity of various strategies, evidence suggests that combining exercise with offers greater benefits than either approach alone. Consequently, this combined strategy has become a preferred method many individuals aiming to maintain health. Calorie restriction, 5/2 intermittent fasting, time-restricted feeding, ketogenic diet among most popular today. Aerobic exercise, resistance training, mixed widely practiced forms physical activity. Exploring best combinations these approaches determine which yields effective results is both meaningful valuable. Despite trend, comparative analysis effects different lacking. This study uses network meta-analysis evaluate impact on body composition compare their efficacy. Methods: We systematically reviewed literature from database inception through May 2024, searching PubMed, Web Science, Embase, Cochrane Library. The was registered in PROSPERO under title: “Effects Combined Different Dietary Interventions Body Composition: A Systematic Review Network Meta-Analysis” (identifier: CRD42024542184). Studies were meticulously selected based specific inclusion exclusion criteria (The included studies must be randomized controlled trials involving healthy adults aged 18 65 years. Articles rigorously screened according specified criteria.), risk bias assessed using tool. Data aggregated analyzed meta-analysis, intervention efficacy ranked by Surface Under Cumulative Ranking (SUCRA) curves. Results: 78 5219 participants, comparing four interventions: calorie restriction (CR+EX), eating (TRF+EX), fasting (5/2F+EX), (KD+EX) composition. Intervention ranking as follows: (1) Weight Reduction: CR+EX > KD+EX TRF+EX 5/2F+EX (Relative CR+EX, effect sizes 5/2F+EX, 2.94 (−3.64, 9.52); 2.37 (−0.40, 5.15); 1.80 (−1.75, 5.34)). (2) BMI: 1.95 (−0.49, 4.39); 2.20 (1.08, 3.32); 1.23 (−0.26, 2.71)). (3) Fat Percentage: 2.66 (−1.56, 6.89); 2.84 (0.56, 5.13); 3.14 (0.52, 5.75).). (4) Lean Mass Male: −1.60 (−6.98, 3.78); −2.76 (−7.93, 2.40)). (5) Female: TRF+EX, −0.52 (−2.58, 1.55); −1.83 (−4.71, 1.04); −2.46 (−5.69,0.76).). Conclusion: emerged percentage while lean mass. For women, proved optimal preserving muscle While effectively reduces weight, it comparatively less at decreasing Hence, considered suboptimal.

Language: Английский

---

Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease

Antioxidants, Journal Year: 2025, Volume and Issue: 14(1), P. 83 - 83

Published: Jan. 13, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by lipid accumulation in the due to an excess their supplies or impairment management. While some patients remain stable for years, a proportion of them progress up steatohepatitis (MASH). MASLD links with systemic pathways being associated metabolic and non-metabolic diseases. Although represents first hit MASLD, pathophysiology its development progression MASH remains not completely understood. Oxidative stress has received particular attention recent as most oxidative process occurs liver, which also target stress-induced damage. Growing evidence linked activity nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) increased production reactive oxygen species damage fibrosis. NOX acts both hepatocytes non-parenchymal hepatic cells, contributing hepatocyte lipotoxicity, impaired microcirculation, stellate, mesenchymal stem cells activation proliferation. This review aims summarize current knowledge on involvement MASLD-MASH transition, focusing role isoforms, suggest targeting therapeutic approach MASLD.

Language: Английский

---

Enhanced accuracy and stability in automated intra-pancreatic fat deposition monitoring of type 2 diabetes mellitus using Dixon MRI and deep learning

Abdominal Radiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

---

Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?

Current Opinion in Nephrology & Hypertension, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which also increasing, with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association. We present here a review associations possible interconnections between these two common processes. Epidemiological studies discordant regarding impact sex on association MASLD incident risk. The nature kidney stones rarely taken into account.A favorable milieu uric acid formation may be created by lower urine pH resulting from defective ammonium production insulin resistance, MASLD.Endogenous oxalate synthesis, major factor calcium stones, increased via decline activity enzymes involved detoxification glyoxylate, immediate precursor oxalate. driving remain to elucidated. Potential mechanisms identified underlying include an increase both stones.

Language: Английский

---

Efficacy of pemafibrate in metabolic dysfunction associated steatotic liver disease and metabolic dysfunction and alcohol associated steatotic liver disease with dyslipidemia: alanine aminotransferase reduction and predictive factors

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

Background: Although pemafibrate has shown promise in treating metabolic dysfunction associated steatotic liver disease (MASLD), reports on its effects and alcohol (MetALD) are limited. The aim of this study was to evaluate the efficacy pemafibrate both conditions complicated with dyslipidemia, focus alanine aminotransferase (ALT) reduction. Predictive factors for treatment response were also identified. Methods: This retrospective, single-center cohort included 96 patients MASLDand14 MetALD treated 24 weeks. Changes function tests, lipid profiles, body mass index analyzed. Factors predicting ALT reduction identified using correlation analysis multivariate regression. Patients categorized as responders or non-responders based changes at Results: After weeks, significant improvements observed tests profiles MASLD; similar benefits found MetALD. median rate -24.75%. Higher baseline aspartate (AST) gamma-glutamyl transferase (GGT) levels greater Baseline AST GGT above upper limit normal predictors Conclusions: Pemafibrate effectively improved MASLD by dyslipidemia. enzyme levels, particularly normal, treatment.

Language: Английский

---

Liver fibrosis progression analyzed with AI predicts renal decline

JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101358 - 101358

Published: Feb. 1, 2025

Language: Английский

---

The burden of cancer in metabolic dysfunction-associated steatotic liver disease

Romanian Journal of Morphology and Embryology, Journal Year: 2025, Volume and Issue: 65(4), P. 627 - 635

Published: Feb. 13, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic worldwide and has become a major public health problem. MASLD frequently progresses to cirrhosis hepatocellular carcinoma, but recent studies also show frequent association with extrahepatic cancers. One of mechanisms involved in both locations insulin resistance hyperinsulinemia. The aim this narrative review was present main etiopathogenic cancer development patients MASLD.

Language: Английский

---

MASH to cirrhosis: bridging the gaps in MASLD management

Acta Clinica Belgica, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: Feb. 24, 2025

Metabolic dysfunction-associated steatohepatitis (MASH) represents a critical stage in the progression of metabolic steatotic liver disease (MASLD), significantly increasing risk cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. Despite rising global prevalence MASLD, gaps understanding pathophysiological mechanisms driving MASH to cirrhosis persist, leading challenges early diagnosis, prevention, treatment. This review explores current knowledge on MASH, focusing its pathophysiology, clinical management, treatment strategies advanced stages. The role dysfunction, portal hypertension, decompensation, HCC occurrence is highlighted, alongside an evaluation therapeutic options including lifestyle intervention, bariatric surgery, pharmacological therapies transplantation. Furthermore, we emphasize need for multidisciplinary care approach improve patient outcomes address complex hepatic interplay MASLD. Bridging these will require integrated effort combining diagnostic tools, novel treatments, comprehensive strategies.

Language: Английский

---